Mekonos
Mekonos is a CGT platform company building the future of cell therapies on a chip. The company’s System on a Chip merges innovations in MEMS, microfluidics, and chemistry for controlled and individualized molecular delivery in cells at scale, offering an integrated solution for advanced cell and gene therapy development from R&D through Manufacturing.
Mekonos’ ex vivo delivery technology uses silicon nanoneedles to enable cargo delivery into any cell type, including primary immune cells and stem cells. The company’s nanoneedle-based delivery system — one needle, one cell — offers a level of precision and consistency unachievable with conventional delivery technologies. The Mekonos platform enables unique cell engineering capabilities, including nuclear delivery, multiplexing and dose control for hyper-precise ex-vivo delivery.
The company is headquartered in San Francisco and is backed by leading investors in both healthcare and technology, including Magnetar Capital, Section 32, Sands Capital, TDK Ventures, Novartis Pharma AG (dRx Capital), the venture arm of Debiopharm, and Elementum Ventures.
